Merck erweitert ADC-Produktionskapazitäten Nordamerika

On By Karl

Verdreifacht Produktionskapazität
70 Million Euro Investment: Merck in Nordamerika ADC-Kapazitäten




Quelle: Merck

1 minute

Anibieter zoom Thema

Der Technologie- and Wissenschaftskonzern Merck is positioned as a second Auftragsentwickler-and-hersteller (CDMO) for the Markt zugelassene ADCs in Nordamerika. St. U.S. Standard Installations for Biological Conjugators in St. Louis are also available for next-generation applications of Nachfrage along with ADS.

Merck, St. Louis acquired Production Capacitor for Antikörper-Wirkstoff-Konjugate (ADCs) in the USA.(Image: Merck)
Merck announces production shutdowns for Antikörper-Wirkstoff-Konjugate (ADCs) in St. Louis, USA.

(Image: Merck)

Standard St. A 70 Million Euro investment in St. Louis, USA; Merck Shuts Down Production of ADCs in Dreifache. During the Capacity, the Prozess-and Analytische Entwicklung (PAD) for Anlagen and Modernization work will enable Merck to make a number of branches for the Biological Conjugate in relation to the Biological Conjugate. Unternehmens’ new products are much more innovative, effective and much more convenient, providing a better market return.

Development of modernization projects in an area of ​​3200 m2 New Workforce Process and analysis, Quality Controls, Forschung and Logistics, New Workforce in terms of Production and Logistics, Special Anlage für die Vorbereitung von Produktionspuffern sowie eines Lagers für die Kühllagerung und Lagerung bei GMP-Control temperature temperature (CRT) eliminates the best temperatures.

Merck achieved good success in the ADC-Herstellungskapazitäten für Kunden weltweit investigation. Im Jahr 2022, Eröffnete to Unternehmen for 59 Million Euros, 6500 m2 We acquired Herstellungskapazitäten for the active drug Wirkstoffe (HPAPIs) for large productions and new Krebstherapeutika ADCs in Verona, Wisconsin, USA.

(ID:50224806)